DCZ0805

DCZ0805 is a novel phosphoramide compound synthesized from osalmide and pterostilbene, developed as an experimental anti-cancer small molecule. It exerts anti-tumor activity against multiple myeloma by arresting cells in the G0/G1 phase and inducing apoptosis via both extrinsic and intrinsic pathways. DCZ0805's mechanism primarily involves inhibition of the NF-κB signaling pathway, contributing to suppression of cell proliferation and survival. Preclinical in vivo studies indicate DCZ0805 can reduce tumor burden in mouse xenograft models with minimal observed toxicity, suggesting potential as a targeted therapy for multiple myeloma[1][3][6][7].